Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
66
Views
8
CrossRef citations to date
0
Altmetric
Original Research

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

Minetta C Liu1 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
,
Wolfgang Janni2 Department of Obstetrics and Gynecology, University Clinic Ulm, Ulm, Germany
,
Vassilis Georgoulias3 Department of Medical Oncology, School of Medicine, University of Crete, Crete, Greece
,
Denise A Yardley4 Department of Medical Oncology, Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, USA
,
Nadia Harbeck5 Department of Breast Center, Oncological Therapy and Clinical Trials Unit, University of Munich (LMU), Munich, GermanyORCID Iconhttps://orcid.org/0000-0002-9744-7372
ORCID Icon,
Xin Wei6 Department of Translational/Clinical Development, Celgene Corporation, Summit, NJ, USA
,
Desmond McGovern7 Department of Clinical Research, Celgene Corporation, Summit, NJ, USA
&
Robert Beck7 Department of Clinical Research, Celgene Corporation, Summit, NJ, USAORCID Iconhttps://orcid.org/0000-0002-1934-9320
ORCID Icon show all
Pages 10427-10433 | Published online: 12 Dec 2019

References

  • Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2(6):351–365. doi:10.1177/175883401037841421789147
  • Pukazhendhi G, Gluck S. Circulating tumor cells in breast cancer. J Carcinog. 2014;13:8. doi:10.4103/1477-3163.13557825191136
  • Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(12):1700–1706. doi:10.1001/jamaoncol.2018.257430054636
  • Menarini Silicon Biosystems Inc. CellSearch Circulating Tumor Cell Kit. [Instructions for Use]. Huntingdon Valley, PA: Menarini Silicon Biosystems Inc; 2017.
  • Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791. doi:10.1056/NEJMoa04076615317891
  • Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218–4224. doi:10.1158/1078-0432.CCR-05-282116857794
  • Bidard F-C, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–414. doi:10.1016/S1470-2045(14)70069-524636208
  • Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153–5159. doi:10.1200/JCO.2008.20.666419752342
  • Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23(3):618–624. doi:10.1093/annonc/mdr26321642515
  • Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483–3489. doi:10.1200/JCO.2014.56.256124888818
  • Yardley DA, Brufsky A, Coleman RE, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575. doi:10.1186/s13063-015-1101-726673577
  • Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018;29(8):1763–1770. doi:10.1093/annonc/mdy20129878040
  • Liu MC, Mego M, Nakamura S, et al. Clinical validity of circulating tumor cells (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). J Clin Oncol. 2011;29(suppl 15):10592 [abstract 10592]. doi:10.1200/jco.2011.29.15_suppl.10592
  • Yan WT, Cui X, Chen Q, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep. 2017;7:43464. doi:10.1038/srep4346428337998
  • Magbanua MJ, Carey LA, DeLuca A, et al. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015;21(5):1098–1105. doi:10.1158/1078-0432.CCR-14-194825524311
  • Yang MH, Imrali A, Heeschen C. Circulating cancer stem cells: the importance to select. Chin J Cancer Res. 2015;27(5):437–449. doi:10.3978/j.issn.1000-9604.2015.04.0826543330
  • Bulfoni M, Gerratana L, Del Ben F, et al. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. Breast Cancer Res. 2016;18(1):30. doi:10.1186/s13058-016-0687-326961140
  • Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–584. doi:10.1126/science.122852223372014

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.